Clinical trial · Observational
Upper GI Serial Tumour Biopsies
Molecular Characterisation of Serial Tumour Samples and Their Correlation With Circulating Biomarkers and Other Biospecimens Taken During the Clinical Course of Patients Receiving Treatment for Upper Gastrointestinal Carcinomas.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): To explore alternative funding streams
Summary
Brief summary (as posted)
This is a prospective translational research study in which tumour samples, blood samples and other biospecimens will be requested from patients with locally advanced or metastatic malignant oesophageal and gastric carcinoma. There are two parts to the study: * Part A - evaluation of serial tumour biopsies * Part B - evaluation of circulating biomarkers and other biospecimens
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Oesophageal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Minor endoscopic biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All participants
- description
- All eligible, consented participants, will be asked to give blood, tissue, and other biospecimens for research purposes
- interventionNames
- Procedure: Minor endoscopic biopsy
Primary outcomes (3)
- measure
- Determine levels of circulating biomarkers in upper GI cancer patients
- timeFrame
- 20 years
- description
- To determine detectable levels of circulating biomarkers in patients with locally advanced and metastatic oesophageal and gastric carcinoma.
- measure
- Correlating levels of biomarkers
- timeFrame
- 20 years
- description
- To correlate circulating biomarker characteristics with serial tumour biopsies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age of 18 years or more. 2. Patients must have given written informed consent. 3. Evidence of locally advanced or metastatic oesophageal and gastric carcinoma, i.e. stage III or IV disease. 4. Accessible tumour that can be safely biopsied using radiological or surgical techniques (if consenting to part A). 5. Full blood count and coagulation tests within acceptable parameters (if consenting to part A). Exclusion Criteria: 1. Inability to provide informed consent. 2. History of significant bleeding disorder (patients on anticoagulation are eligible if the anticoagulation can be safely managed to allow fresh tumour biopsies and blood sampling). 3. History of HIV, Hepatitis B/C or other transmissible human disease. 4. Any conditions where research biopsies or blood sampling may increase risk of complications for the patient and/or investigator, including high risk groups such as intravenous drug users.
References
Publications (0)
Data not yet available